I need more of the filing content to produce an accurate article. The filing text cuts off mid-sentence in the balance sheets section. However, I can work with what's available from the cover page and table of contents to produce a limited but accurate article. Let me assess the substantive disclosure content available. The filing does contain substantive content: the forward-looking statements section lists specific risk factors, and the cover page confirms share count (100,363,253 shares as of August 7, 2026), company identity, filing period (Q2 ended June 30, 2026), and exchange/ticker information. The filing is a 10-Q for the quarterly period ended June 30, 2026. However, the financial statements themselves are cut off before any figures are visible. I'll produce the article based solely on what is confirmed in the source text.

Shattuck Labs, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the Securities and Exchange Commission, with the report made available on August 11, 2026.

Key Highlights

  • Share count: As of August 7, 2026, Shattuck Labs had 100,363,253 shares of common stock, $0.0001 par value per share, outstanding.
  • Reporting period: The quarterly report covers the three and six months ended June 30, 2026, with comparative periods ending June 30, 2025.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Exchange listing: Common stock is listed on NASDAQ:STTK on The Nasdaq Global Select Market.
  • Principal offices: The company is headquartered at 500 W. 5th Street, Suite 1200, Austin, TX 78701.

Shattuck Labs Q2 2026 10-Q: Filing Overview and Disclosed Risk Factors

Shattuck Labs, Inc. (NASDAQ:STTK) submitted its quarterly report on Form 10-Q for the period ended June 30, 2026, according to the filing. The company reported 100,363,253 shares of common stock outstanding as of August 7, 2026. The filing covers condensed financial statements for the three and six months ended June 30, 2026, including balance sheets, statements of operations and comprehensive loss, statements of changes in stockholders' equity, and statements of cash flows, alongside management's discussion and analysis.

The filing includes an extensive cautionary note on forward-looking statements, which the company describes as "subject to substantial risks and uncertainties and are based on estimates and assumptions." Among the risk factors the company identified are the timing and progress of nonclinical studies and clinical trials, patient enrollment in clinical trials, costs related to research and development programs, and the impact of inflationary pressures on such costs. The company also cited its ability to retain key executives, advance product candidates through clinical stages, and obtain regulatory approvals as areas of uncertainty.

Additional risks disclosed in the filing include the company's ability to enter into strategic arrangements, contract with third-party suppliers and manufacturers, protect intellectual property rights, and obtain additional financing. The company also noted macroeconomic conditions as a risk factor, including "economic downturns, inflation, fluctuating interest rates, changes in trade policies, including tariffs or other trade restrictions," as well as geopolitical events and public health crises. The company expressly stated it "cannot assure you that we will realize the results, outcomes, benefits or developments that we expect or anticipate."

What Was Disclosed

Shattuck Labs filed its quarterly report covering the period ended June 30, 2026, disclosing its share count of 100,363,253 as of August 7, 2026, its filer status as a non-accelerated and smaller reporting company, and an extensive set of forward-looking risk factors tied to its clinical and operational activities.